Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
Alimentary Pharmacology & Therapeutics · 2024-10 · 60 (8) · 1005-1020
DOI: 10.1111/apt.18202 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-08-12. Written by Parminder Kaur and 13 co-authors. Institution: Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Major MEDLINE topics: Decorin, Disease Progression, Liver Diseases, Alcoholic, Myostatin. Cited 11 times so far (Crossref); 51 references. Funded by: Indian Council of Medical Research.
Abstract (original language)
Background and Aims Myokines are the muscle‐derived hormones orchestrating muscle and systemic health. Their role in the progression of alcohol‐associated liver disease (ALD) remains elusive.
Methods
Three‐hundred‐one patients across the spectrum of ALD including fatty liver (FL, N = 13), compensated cirrhosis (CC, N = 17), non‐acute decompensation (NAD, N = 95), acute decompensation (AD, N = 51) and acute‐on‐chronic liver failure (ACLF, N = 125) were recruited between 2021 and 2023. Plasma myostatin, decorin levels, nutritional status, handgrip strength (HGS), systemic inflammation, infection, ammonia, disease course and 30‐day mortality were recorded.
Results
Patients aged 48 years (IQR: 38–52) and 97.7% of males were enrolled. Myostatin was elevated while decorin was reduced in cirrhosis compared to without cirrhosis, and further in DC compared to CC ( p < 0.001). A step‐wise increase in myostatin and reduction in decorin was observed transitioning from NAD to AD to ACLF ( p < 0.001). Myostatin was further increased and decorin was reduced along with the grades and organ failures in AD and ACLF ( p < 0.001, each). Baseline decorin (AUC: 0.797) and its combination with MELD (AUC: 0.814) predicted disease resolution in AD and ACLF. Although, both myostatin (aOR: 18.96) and decorin (aOR: 0.02) could predict mortality, decorin was independent (aOR: 0.04) and additive to MELD (AUC of MELD+ log Decorin + log TLC + HE‐grade:0.815); p < 0.05 each. Myostatin increased and decorin reduced with inflammation, hyperammonaemia, malnutrition and HGS in AD and ACLF ( p < 0.05, each).
Conclusion
Myokines are linked with malnutrition, fibrosis, systemic inflammation, organ failures, disease course and mortality in ALD. Decorin enhances the risk estimation of mortality of MELD in AD and ACLF. Therapeutic modulation of myokines is a potentially disease‐modifying target in ALD.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Translational and Regenerative Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
- University of Louisville School of Medicine, Louisville, Kentucky, USA.
ORCID profiles: Nipun Verma, Sahaj Rathi, Arka De, Madhumita Premkumar, Sunil Taneja, Ashwani K Singal, Ajay Duseja
Funding
- Indian Council of Medical Research
Cite
APA
Kaur, P., Verma, N., Garg, P., Ralmilay, S., Wadhawan, A., Nadda, R., Prajapati, J., Sharma, G., Rathi, S., De, A., Premkumar, M., Taneja, S., Singal, A. K., & Duseja, A. (2024). Myokines are associated with progression, course and mortality in alcohol‐associated liver disease. Alimentary Pharmacology & Therapeutics, 60(8), 1005-1020. https://doi.org/10.1111/apt.18202
Vancouver
Kaur P, Verma N, Garg P, Ralmilay S, Wadhawan A, Nadda R, et al. Myokines are associated with progression, course and mortality in alcohol‐associated liver disease. Alimentary Pharmacology & Therapeutics. 2024;60(8):1005-1020. doi:10.1111/apt.18202
BibTeX
@article{Kaur2024,
author = {Kaur, Parminder and Verma, Nipun and Garg, Pratibha and Ralmilay, Samonee and Wadhawan, Aishani and Nadda, Rohit and Prajapati, Jiya and Sharma, Gaurav and Rathi, Sahaj and De, Arka and Premkumar, Madhumita and Taneja, Sunil and Singal, Ashwani K and Duseja, Ajay},
title = {Myokines are associated with progression, course and mortality in alcohol‐associated liver disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {8},
pages = {1005--1020},
doi = {10.1111/apt.18202}
}
EUVIMED